Global /China /Healthcare /Drug Manufacturers - General /600420
chevron_leftBack
Shanghai Shyndec Pharmaceutical Co., Ltd. logo

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420
SSE: 600420 Delayed
9.59CNY -0.1%
1.42 USD
As of 14 June 2026, Shanghai Shyndec Pharmaceutical Co., Ltd. has a market cap of $1.9B USD, ranking #7293 globally and #1815 in China. It ranks #590 in the Healthcare sector, and #233 in the Drug Manufacturers - General industry.
Global Rank
7293
Country Rank
1815
Sector Rank
590
Industry Rank
233
Key Stats
Market Cap
$1.9BUSD
12.88B CNY
Enterprise Value
$1.17BUSD
7.92B CNY
Revenue (TTM)
$1.38BUSD
9.36B CNY
EBITDA (TTM)
$267.81MUSD
1.81B CNY
Net Income (TTM)
$138.96MUSD
941.6M CNY
EBITDA Margin
19%
Profit Margin
10%
PE Ratio
13.7
PS Ratio
1.4
PB Ratio
0.8
EV/EBITDA
4.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yong Liu open_in_new
Employees
9,697
Founded
1996
Website
shyndec.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.1% -1.6% -7.3% -9.5% -11% -5.9%

News

Loading...

Markets

Exchange Ticker Price
Shanghai Stock Exchange
MIC: XSHG
PRIMARY
600420
上海现代制药股份有限公司 Class A
ISIN: CNE000001JG2
Shares Out.:
1.341B1 Shares Float: 695.761M2
TV:
SA:
YF:
GF:
BA:
MS:
9.59 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Shyndec Pharmaceutical Co., Ltd.

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and develops, produce, and sell of pharmaceutical products in China. The company offers nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and cefdinir dispersible tablets. It also offers nifedipine controlled-release tablets, amlodipine besylate tablets, enalapril maleate tablet, pravastatin sodium tablets, olmesartan medoxomil hydrochlorothiazide tablets, olmesartan amlodipine tablets; milnaprom hydrochloride tablets, lofen codeine tablets, gastrodin injection, naloxone hydrochloride injection, piracetam injection; and apmis film, tacrolimus capsules, mannan peptide for injection, imatinib mesylate. In addition, the company provides methylprednisolone sodium succinate for injection, octreotide acetate injection, betamethasone sodium phosphate for injection, dexamethasone sodium phosphate injection; diclofenac sodium sustained release tablets; 6-aminopenicillinic acid, azithromycin, amoxicillin, potassium clavulanate microcrystalline cellulose, ceftriaxone sodium crude salt, 7-aminocephalosporanic acid, chorionic gonadotropin, urinary gonadotropin; and naphazoline hydrochloride nasal drops, Ambroxol Hydrochloride Oral Solution. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.85B
364.89B CNY
3K%
44.9
603259
$49.64B
336.36B CNY
3K%
17.2
$28.52B
223.48B HKD
1K%
35.7
$18.8B
147.32B HKD
889%
162.3
$16.51B
111.89B CNY
769%
-
9926
$16.01B
125.46B HKD
742%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
40K%
38.1
JNJ
$547.28B
29K%
26.4
ABBV
$360.63B
19K%
97.4
$321.52B
256.25B CHF
17K%
19.9
AZN
$288.84B
215.59B GBP
15K%
27.6
NOVN
$274.65B
218.9B CHF
14K%
20.5
chevron_leftBack